Eli Lilly and Company is expanding its domestic pharmaceutical manufacturing footprint with an additional $4.5 billion investment across its Lebanon, Indiana, production sites, while also opening its first dedicated genetic medicine manufacturing facility.
The latest commitment brings Lilly’s total Indiana capital expansion investment since 2020 to more than $21 billion, reinforcing the company’s long-term focus on scaling U.S.-based pharmaceutical production capacity to support growing demand for advanced therapies and metabolic disease treatments.
The investment will support expanded capabilities at Lilly Lebanon API, one of the company’s future active pharmaceutical ingredient production facilities, and Lilly Lebanon Advanced Therapies, which officially opened this week.
Lilly Lebanon Advanced Therapies is the company’s first dedicated manufacturing facility focused on genetic medicines.
The site is designed to support both clinical and commercial-scale production of therapies targeting disease at the genetic level, including a range of advanced treatment modalities from early-stage development through large-scale supply.
According to Lilly, designing the facility required the development of new manufacturing processes without established commercial precedent, highlighting the growing complexity of next-generation pharmaceutical production infrastructure.
The facility is the first of three planned manufacturing sites on the Lebanon campus, which will also include Lilly Lebanon API and the Lilly Medicine Foundry.
The Lebanon API site is expected to manufacture several of Lilly’s key metabolic disease products, including:
When completed, the Lebanon API facility is expected to become the largest API production site in U.S. history.
“From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world’s most advanced plants to make them,” said David A. Ricks, Lilly chair and CEO.
The announcement reflects broader industry efforts to strengthen domestic pharmaceutical manufacturing capacity and reduce supply chain risk through increased U.S.-based production.
U.S. capital expansion commitments since 2020 now total more than $50 billion, supported by policies promoting domestic manufacturing investment and the company plans to begin construction on several newly announced U.S. manufacturing facilities later this year.
Indiana Governor Mike Braun said the investment reinforces the state’s position within the life sciences manufacturing sector.
“With this investment in Lebanon and across the state, Indiana is reinforcing its position as a prime destination for life sciences and advanced manufacturing, spanning innovation, production and global distribution,” Braun said.
According to findings from an upcoming Indiana University Kelley School of Business report cited by Lilly, the company accounts for 70% of Indiana’s pharmaceutical GDP, with every Lilly job supporting more than two additional jobs statewide.
Lilly also estimates that every dollar it spends locally generates up to four dollars in additional regional economic activity.
The Lebanon manufacturing campus has become a central component of Lilly’s domestic production strategy as pharmaceutical companies continue increasing investment in advanced biologics, obesity therapies, and next-generation genetic medicines.
“Lilly’s sustained investments since 2020 underscore the growing strength of Indiana’s life sciences sector,” said Indiana University President Pamela Whitten. “Progress at this scale is possible only through robust partnerships.”
